Código QR

Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis

ABSTRACT Background Rademikibart, a potent, next‐generation, optimized IL‐4Rα‐targeting antibody, achieved its primary and secondary endpoints as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2, randomized, double‐blind, placebo‐controlled trial (NC...

Descrición completa

Gardado en:
Principais autores: Jonathan I. Silverberg, Emma Guttman‐Yassky, Raúl Collazo
Formato: Artigo
Idioma:Inglês
Publicado: Wiley 2026-06-01
Series:JEADV Clinical Practice
Assuntos:
atopic dermatitis
dosing frequency
efficacy
quality of life
rademikibart
sleep
Acceso en liña:https://doi.org/10.1002/jvc2.70200
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares